“BioXcel Therapeutics Inc. ( BTAI ) announced proof-of-concept data from its Phase 1 study of IV (intravenous) dexmedetomidine or Dex for acute treatment of agitation in patients with Senile Dementia of the Alzheimer’s Type or SDAT”
Read the full story at nasdaq.com
BioXcel Announces Positive Data On Senile Dementia Of Alzheimer’s Type; Stock Up | NASDAQ
More from BusinessMore posts in Business »
- Biogen Stays the Wrong Course After a Key Drug Failure
- What Happened? Alzheon Leaves IPO on the Table for the Second Time | Biospace
- Biogen Inks Two Deals to Make Drugs for Neurological Diseases | NASDAQ
- AC Immune inks $1.7bn deal with Lilly, strategic partnership with WuXi | Outsourcing Pharma
- Braincheck Raises Another $1.5 Million to Bring Artificial Intelligence to Dementia Care | PR Web